COVID-19 Journal Publications
This page includes links to Lilly sponsored clinical trials that have been published in peer reviewed journals within the last 5 years. Each section is sorted by product and may be expanded by each phase. The list of publications below is limited to products that have been approved for use and may contain information about doses, delivery devices, uses, formulations and populations different from product labeling. Clinical decisions should be based on the full safety and efficacy information contained in the product's Full Prescribing Information in the provided link below.
If you have questions about a Lilly study not listed below or would like to request an electronic copy of one of the journal publications on this page, please Contact Lilly services.
bamlanivimab
Healthcare providers should direct questions about bamlanivimab alone or about the revocation of Emergency Use Authorization (EUA) 90, Eli Lilly and Company
at 1-855-LillyC19 (1-855-545-5921)
Bamlanivimab has not been approved, but has been authorized for emergency use by FDA, to treat mild to moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progressing to severe COVID-19 and/or hospitalization*.* Bamlanivimab is an investigational drug that has not been approved by the FDA for any use. It is not yet known if bamlanivimab is safe and effective for the treatment of COVID-19. This use is authorized only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use, unless the authorization is terminated or revoked sooner.
bamlanivimab and etesevimab together
HCP Fact Sheet | Patient & Caregiver Fact Sheet | FDA Authorization Letter
Bamlanivimab and etesevimab together is authorized for use under an Emergency Use Authorization for the treatment of mild to moderate COVID-19 illness in adults and pediatric patients 12 years and older, who weigh at least 40 kg, who are at high risk for progressing to severe COVID-19 illness and/or hospitalization. Bamlanivimab and etesevimab together is an investigational drug that has not been approved by the FDA for any use. It is not yet known if bamlanivimab and etesevimab together is safe and effective for the treatment of COVID-19. This use is authorized only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use, unless the authorization is terminated or revoked sooner.